Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
," The Journal of Immunology, vol.
The white blood cells normally used in adoptive immunotherapy
have traditionally been collected from patients after they have fallen ill and are invariably affected by the disease or illness which has struck down the whole body.
A major difficulty in adoptive immunotherapy
has been identifying those lymphocytes among all those present in the body that are most active against a tumor.
Karl Peggs, and other members of the UCL department of hematology, who are global leaders in adoptive immunotherapy
, will work with Cellectis towards in vivo proof of concept and clinical translation of this strategy.
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy
for the treatment of solid tumors," Expert Opinion on Biological Therapy, vol.
Cellectis founded the field of gene editing 14 years ago and is now primarily focused on adoptive immunotherapy
using TALEN -engineered T cells combined with (CARs).
At the 27th Annual Meeting, prominent investigators summarized central themes and recent research in tumor immunology and cancer immunotherapy including innate immunity, dendritic cells, T cell differentiation, antibody therapy, and the tumor microenvironment as well as recent advances in the clinical application of cancer vaccines, coinhibition and costimulation of immune cells for immunotherapy, adoptive immunotherapy
, and immune monitoring in clinical trials of cancer immunotherapies.
Hematology/Medical Oncology: Hem-Onc Authorization Guideline Notes; Adjuvant Chemotherapy; Adoptive immunotherapy
(AIT); Anti-emetic therapy; Antineoplaston therapy; Blood-brain barrier disruption by osmotic agents - coverage; Bone marrow/Stem cell transplant (BMT); Chemotherapy; Umbilical cord blood compatibility testing; Chemoresistance assays/Tumor chemosensitivity; Colorectal cancer therapy; Colon cancer - KRAS Gene Mutation Test; Cryosurgical ablation hepatic lesions; Dendritic cell immunotherapy for cancer; Donor Lymphocyte/Leukocyte Infusions;
Cell Medica's own lead product, adoptive immunotherapy
for cytomegalovirus infections (AIM-CMV), is currently being tested in a Phase III clinical trial across 14 hospitals in the UK.